Clinical Trial Update: Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating sequential hypofractionated radiotherapy followed by the anti-PD-L1 agent atezolizumab for recurrent small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Small Cell Lung Cancer Recurrent | Phase 2 | Status: UNKNOWN